Comparison of good review practices of seven countries participating in the ECOWAS medicines regulatory harmonisation initiative: identifying opportunities for improvement.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-01-10 eCollection Date: 2024-01-01 DOI:10.3389/fmed.2024.1520892
Mercy Owusu-Asante, Delese Mimi Darko, Seth Seaneke, Aminata Nacoulma, Oula Ibrahim Olivier Traore, Christianah Mojisola Adeyeye, Abayomi Akinyemi, Coulibaly Assane, Clarisse Épse Kaul Meledje Clamoungou, Oumy Kalsoum Ndao, Rokhaya Ndiaye Kande, James Komeh, Sheku Mansaray, Dalkoi Lamboni, Maheza Agba, Stuart Walker, Sam Salek
{"title":"Comparison of good review practices of seven countries participating in the ECOWAS medicines regulatory harmonisation initiative: identifying opportunities for improvement.","authors":"Mercy Owusu-Asante, Delese Mimi Darko, Seth Seaneke, Aminata Nacoulma, Oula Ibrahim Olivier Traore, Christianah Mojisola Adeyeye, Abayomi Akinyemi, Coulibaly Assane, Clarisse Épse Kaul Meledje Clamoungou, Oumy Kalsoum Ndao, Rokhaya Ndiaye Kande, James Komeh, Sheku Mansaray, Dalkoi Lamboni, Maheza Agba, Stuart Walker, Sam Salek","doi":"10.3389/fmed.2024.1520892","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>When implemented by national and regional regulatory agencies good review practices (GRevPs) support the timely high-quality review of medicines for enhanced patients' availability to safe, quality and efficacious innovative and generic products. It is important that all aspects of GRevPs are continuously evaluated and updated to promote the continuous improvement of regulatory systems at national and regional levels. The aim of this study was to assess and compare the GRevPs of the national medicines regulatory agencies (NMRAs) of Burkina Faso, Cote d'Ivoire, Ghana, Nigeria, Senegal, Sierra Leone and Togo, who are active participants of the ECOWASMRH initiative to identify opportunities for improvement.</p><p><strong>Methods: </strong>The Optimising Efficiencies in Regulatory Agencies questionnaire, was completed by each of the NMRAs, which facilitates the assessment of GRevPs, which in turn affect the regulatory review processes.</p><p><strong>Results: </strong>Except for Cote d'Ivoire and Nigeria which are autonomous, the other five NMRAs operate within the administrative structure of their respective Health Ministry, to regulate medical products for human use, medical devices and diagnostics. Apart from Togo, the agencies receive partial funding from their governments as well as from regulatory fees. Population in the seven countries ranges from 8.6 million to 211.4 million. All the NMRAs had measures in place to achieve quality in their review processes, although there were some remaining initiatives related to transparency and communication, continuous improvement and training and education, to be implemented. Of the ten quality decision-making practices Ghana had implemented nine into a framework, Togo eight, Cote d'Ivoire seven, Nigeria six, and Burkina Faso five; while Sierra Leone has partially implemented all ten and Senegal had not implemented any of the quality decision-making practices.</p><p><strong>Conclusion: </strong>The study compared the organisation, GRevPs and quality decision-making processes of the NMRAs that actively participate in the ECOWAS-MRH initiative. Though some differences were identified with regard to organisation, a significant number of good review practice initiatives and quality decision-making practices were identified yet to be implemented to promote continuous improvement in the regulatory processes of the NMRAs.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1520892"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757867/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1520892","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: When implemented by national and regional regulatory agencies good review practices (GRevPs) support the timely high-quality review of medicines for enhanced patients' availability to safe, quality and efficacious innovative and generic products. It is important that all aspects of GRevPs are continuously evaluated and updated to promote the continuous improvement of regulatory systems at national and regional levels. The aim of this study was to assess and compare the GRevPs of the national medicines regulatory agencies (NMRAs) of Burkina Faso, Cote d'Ivoire, Ghana, Nigeria, Senegal, Sierra Leone and Togo, who are active participants of the ECOWASMRH initiative to identify opportunities for improvement.

Methods: The Optimising Efficiencies in Regulatory Agencies questionnaire, was completed by each of the NMRAs, which facilitates the assessment of GRevPs, which in turn affect the regulatory review processes.

Results: Except for Cote d'Ivoire and Nigeria which are autonomous, the other five NMRAs operate within the administrative structure of their respective Health Ministry, to regulate medical products for human use, medical devices and diagnostics. Apart from Togo, the agencies receive partial funding from their governments as well as from regulatory fees. Population in the seven countries ranges from 8.6 million to 211.4 million. All the NMRAs had measures in place to achieve quality in their review processes, although there were some remaining initiatives related to transparency and communication, continuous improvement and training and education, to be implemented. Of the ten quality decision-making practices Ghana had implemented nine into a framework, Togo eight, Cote d'Ivoire seven, Nigeria six, and Burkina Faso five; while Sierra Leone has partially implemented all ten and Senegal had not implemented any of the quality decision-making practices.

Conclusion: The study compared the organisation, GRevPs and quality decision-making processes of the NMRAs that actively participate in the ECOWAS-MRH initiative. Though some differences were identified with regard to organisation, a significant number of good review practice initiatives and quality decision-making practices were identified yet to be implemented to promote continuous improvement in the regulatory processes of the NMRAs.

导言:国家和地区监管机构实施良好审评做法(GRevPs)有助于及时对药品进行高质量的审评,使患者更容易获得安全、优质、有效的创新产品和非专利产品。对良好审评实践的各个方面进行持续评估和更新,以促进国家和地区监管系统的不断改进,这一点非常重要。本研究旨在评估和比较布基纳法索、科特迪瓦、加纳、尼日利亚、塞内加尔、塞拉利昂和多哥国家药品监管机构(NMRAs)的 GRevPs,以确定改进的机会:方法:每个国家医疗监管机构都填写了 "优化监管机构效率 "调查问卷,这有助于评估全球风险和政策,进而影响监管审查程序:结果:除科特迪瓦和尼日利亚拥有自主权外,其他五个国家医疗器械监管机构均在各自卫生部的行政架构内运作,负责监管人用医疗产品、医疗器械和诊断产品。除多哥外,这些机构的部分资金来自政府以及监管费用。这七个国家的人口从 860 万到 2.114 亿不等。尽管在透明度和沟通、持续改进以及培训和教育方面仍有一些举措有待实施,但所有国家医疗器械监管局都已采取措施,以提高审查过程的质量。在十项优质决策做法中,加纳在一个框架内实施了九项,多哥实施了八项,科特迪瓦实施了七项,尼日利亚实施了六项,布基纳法索实施了五项;而塞拉利昂部分实施了所有十项,塞内加尔没有实施任何一项优质决策做法:本研究比较了积极参与西非国家经济共同体(ECOWAS)--MRH 倡议的非驻地机构的组织、GRevPs 和质量决策过程。虽然在组织方面发现了一些差异,但也发现了大量尚待实施的良好审查做法倡议和优质决策做法,以促进非物资监管机构监管流程的持续改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信